arrow
M

Mark Opdam

netherlands cancer institute
H指数:23
被引数:1,236

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Label-efficient computational tumour infiltrating lymphocyte assessment in breast cancer (ECTIL): multicentre validation in 2340 patients with breast cancer

标签高效的计算肿瘤浸润淋巴细胞评估在乳腺癌中的应用(ECTIL):在2340例乳腺癌患者中的多中心验证

2025-12-100
OAAI
Prognostic value of histopathologic traits independent of stromal tumor-infiltrating lymphocyte levels in chemotherapy-naïve patients with triple-negative breast cancer
2024-03-010
OAAI
Long-term outcomes of young, node-negative, chemotherapy-naïve, triple-negative breast cancer patients according to BRCA1 status

根据BRCA1状态的年轻,淋巴结阴性,化疗初治,三阴性乳腺癌患者的长期结果

2024-01-090
OAAI
External validation and clinical utility assessment of PREDICT breast cancer prognostic model in young, systemic treatment-naïve women with node-negative breast cancer

预测乳腺癌预后模型的外部验证和临床效用评估年轻,未经全身治疗的淋巴结阴性乳腺癌妇女

2023-12-010
OA
Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity

管腔型乳腺癌的身份取决于糖皮质激素受体活性的丧失

2023-10-305
OAAI
MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer

MYC是乳腺癌中mTOR抑制剂耐药的临床重要驱动因素

2023-08-291
OAAI
Multiscale deep learning framework captures systemic immune features in lymph nodes predictive of triple negative breast cancer outcome in large-scale studies
2023-05-258
OAAI
Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial

根据HRD/BRCAwt基因组图谱的HIPEC在III期卵巢癌中的作用: 来自III期OVHIPEC试验的结果

2022-06-0430
OA
Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature
2022-05-199
OAAI
Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients

早期三阴性乳腺癌患者中含卡培他滨的辅助化疗获益和同源重组缺陷

2022-02-0512
OA